PROSUS 39.190 € (-0,75 %) 
INPOST 15.490 € (+0,13 %) 
WORLDLINE 9.519 € (-1,07 %) CARREFOUR 16.640 € (+0,15 %) VEOLIA ENVIRON. 37.460 € (+1,38 %) COMPAGNIE ODET 1 438.000 € (-1,10 %) CSG 14.056 € (+6,23 %) ASML HOLDING 1 555.800 € (+0,97 %) LEGRAND 142.000 € (+1,97 %) PHILIPS KON 23.010 € (-4,48 %) ADP 109.100 € (-2,06 %) AALBERTS NV 40.000 € (+1,01 %) V LANSCHOT KEMPEN 67.300 € (+0,67 %) CRCAM SUD R.A.CCI 217.000 € (-0,46 %) 
SHELL PLC 36.865 € (+0,99 %) TECHNIP ENERGIES 32.980 € (-0,30 %) NN GROUP 77.480 € (+1,81 %) RENAULT 25.840 € (-1,30 %) CAPGEMINI 90.140 € (-1,62 %) APERAM 46.860 € (-0,68 %) ARCELORMITTAL SA 58.720 € (+1,17 %) 
DSM FIRMENICH AG 84.940 € (+1,34 %) ING GROEP N.V. 28.745 € (+1,14 %) BE SEMICONDUCTOR 251.600 € (+1,86 %) HEINEKEN 75.840 € (+0,05 %) AHOLD DEL 36.120 € (+1,46 %) UNILEVER 53.530 € (-0,50 %) RELX 28.800 € (-1,44 %) KPN KON 4.345 € (+0,25 %) WOLTERS KLUWER 61.260 € (-1,89 %) IMCD 91.580 € (+6,24 %) 
AEGON 7.836 € (+1,79 %) SBM OFFSHORE 32.100 € (-0,74 %) MAGNUM 16.306 € (+0,27 %) QUADIENT 11.960 € (-0,83 %) SOITEC 102.750 € (+5,00 %) PLANISWARE 20.650 € (-1,67 %) SYNERGIE 28.100 € (-0,35 %) AKZO NOBEL 57.340 € (-0,24 %) AIR LIQUIDE 178.520 € (+1,01 %) PERNOD RICARD 63.480 € (-1,15 %) ASM INTERNATIONAL 927.600 € (+4,27 %) SPIE 47.900 € (+0,42 %) NANOBIOTIX 36.200 € (+3,61 %) FORVIA 8.980 € (-2,79 %) LVMH 482.950 € (-1,74 %) HEIJMANS KON 96.150 € (-0,77 %) SAINT GOBAIN 74.620 € (-0,35 %) VALERIO TX 0.429 € (+7,25 %) ADYEN 827.500 € (-1,92 %) MICHELIN 34.180 € (-1,58 %) LIGHTON 5.060 € (-4,71 %) BENETEAU 6.080 € (-0,82 %) KERING 244.250 € (-2,44 %) TOTALENERGIES 71.200 € (+1,11 %) IPSOS 35.360 € (+0,57 %) BNP PARIBAS ACT.A 102.320 € (+1,39 %) CAFOM 13.300 € (-3,62 %) ESSILORLUXOTTICA 165.150 € (-2,51 %) 
MAROC TELECOM 8.800 € (0,00 %) |
28/04/2023 10:04
EQS-Adhoc: Biotest AG: Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raisedEQS-Ad-hoc: Biotest AG / Key word(s): Alliance Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)
Biotest and Grifols further strengthen their cooperation - EBIT forecast 2023 significantly raised
Dreieich, 28 April 2023. The Supervisory Board approved the signing and execution of several agreements by the Board of Management to further strengthen the cooperation between Grifols S.A. and Biotest AG in research & development, manufacturing, operations as well as sales and distribution. A Technology Transfer Agreement and a License Agreement will ensure that the new product developments of Biotest will be manufactured and commercialized worldwide by also using the organization and facilities of Grifols. A payment for the transferred technology and later royalty payments depending on net sales of the licensed products were agreed as consideration. The payment for the technology will have a positive effect on the EBIT of Biotest in a triple-digit million range. The Board of Management raises the EBIT guidance for 2023 given in March 2023 from € -15 to -20 million to a level that can possibly exceed € 100 million. A more specific statement is subject to revenue recognition considerations regarding final project milestones. Biotest Aktiengesellschaft Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.com
Disclaimer This document contains forward-looking statements on the overall economic development and the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on the company's current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties that could cause actual developments to differ materially from those anticipated. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and does not assume any obligation to do so.
About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest is part of the Grifols Group, Barcelona, Spain (www.grifols.com).
IR contact Dr Monika Buttkereit Phone: +49-6103-801-4406
PR contact Dirk Neumüller Phone: +49-6103-801-269
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Contact: Dr. Michael Ramroth Chief Financial Officer Biotest AG Landsteinerstr. 3 63303 Dreieich Tel. +40 6103 801 338 Fax: +49 6103 801 347 Michael.ramroth@biotest.com End of Inside Information 28-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
1620119 28-Apr-2023 CET/CEST Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière